Moderna doubles size of COVID-19 vaccine pediatric study

Moderna Inc is planning to double the size of an ongoing trial testing its COVID-19 vaccines in children aged six months to less than 12 years.

According to updated details on clinical trial record site clinicaltrials.gov, the study will now enroll an estimated 13,275 participants, nearly double the earlier target of 6,975 participants. In July, Moderna said it was in discussions with the U.S. Food & Drug Administration to expand the study with an objective to enroll a larger safety database, which increases the likelihood of detecting rarer events.